% Patients with Insufficient Bone
Formation
Delta p-value
Gender Male Female
17 45 -28 0.44
Type of Distraction
Used
External Internal
43 25 28 1.0
Use of HBO
Yes No
29 30 -1.4 1.0
Table S1. Incidence of insufficient bone formation in the distractor gap stratified by categorical variables. *, p<0.05
Patients with Insufficient
Bone Formation
Patients without Insufficient Bone Formation
Age 52.4 46.6 5.9 1.0
Publication Year 2006.9 2008.3 -1.4 1.0
Dosage (Gy) 53.1 51.5 1.5 1.0
Defect Size
(mm) 45.5 48.3 -2.8 1.0
Latency Period
(days) 7.4 8.8 -1.5 0.15
Distraction Rate
(mm/day) 0.71 0.70 0.012 1.0
Total Amount of
DO (mm) 19.5 27.2 -7.7 1.0
Consolidation
Period (wks) 18.3 17.5 0.82 1.0
Table S2. Incidence of insufficient bone formation in the distractor gap stratified by numerical variables. *, p<0.05
% Patients with
Fractures Delta p-value
Gender Male Female
8.7 18 -9.4 1.0
Type of Distraction
Used
External Internal
0 20 -20 1.0
Use of HBO
Yes No
0 30 -30 0.92
Table S3. Incidence of fracture stratified by categorical variables. *, p<0.05
Publication Year 2007.0 2008.0 -1.0 1.0
Dosage (Gy) 61.3 50.4 10.9 0.38
Defect Size (mm) 38.3 50.2 -11.8 1.0
Latency Period
(days) 9.0 8.4 0.61 1.0
Distraction Rate
(mm/day) 0.63 0.72 -0.091 1.0
Total Amount of
DO (mm) 30.3 25.6 4.8 1.0
Consolidation
Period (wks) 16.0 17.6 -1.6 1.0
Table S4. Incidence of fracture stratified by numerical variables. *, p<0.05
% Patients with
Intraoral Exposure Delta p-value
Gender Male Female
8.7 18 -9.5 1.0
Type of Distraction
Used
External Internal
14 15 -0.7 1.0
Use of HBO
Yes No
14 30 -16 1.0
Table S5. Incidence of intraoral exposure stratified by categorical variables. *, p<0.05
Patients with Intraoral Exposure
Patients without Intraoral Exposure
Age 48.0 48.1 -0.1 1.0
Publication Year 2006.5 2008.1 -1.6 0.44
Dosage (Gy) 61.0 49.9 11.2 0.24
Defect Size (mm) 36.7 50.5 -13.9 0.56
Latency Period
(days) 10.0 8.3 1.7 0.76
Distraction Rate
(mm/day) 0.60 0.72 -0.12 1.0
Total Amount of
DO (mm) 30.3 25.6 4.8 1.0
Consolidation
Period (wks) 15.7 17.8 -2.1 1.0
Table S6. Incidence of intraoral exposure stratified by numerical variables. *, p<0.05
% Patients with
Cutaneous Exposure Delta p-value
Gender Male Female
4.3 27 -23 0.35
Type of Distraction
Used
External Internal
0 20 -20 1.0
Use of HBO
Yes No
0 20 -20 1.0
Table S7. Incidence of cutaneous exposure stratified by categorical variables. *, p<0.05
Patients with Cutaneous
Exposure
Patients without Cutaneous
Exposure
Age 50.3 37.8 2.4 1.0
Publication Year 2009.0 2007.8 1.2 1.0
Dosage (Gy) 65.0 50.6 14.4 0.40
Defect Size (mm) 32.0 50.2 -18.2 0.12
Latency Period
(days) 9.0 8.4 0.61 1.0
Distraction Rate
(mm/day) 0.75 0.70 0.052 1.0
Total Amount of
DO (mm) 36.0 25.2 10.8 0.36
Consolidation
Period (wks) 16.0 17.6 -1.6 1.0
Table S8. Incidence of cutaneous exposure incidence stratified by numerical variables. *, p<0.05
